Outsourced Pharma App Notes & Case Studies

  1. Preparing Sales, Marketing And Technology Teams To Win Today’s Customer

    As today’s information-craving customers force the life sciences industry to change their sales and marketing model, innovative customer engagement models are sought as a revenue-generation lever. Message reach and frequency no longer equate to sales. Now it’s about building and sustaining customer loyalty by delivering value. Top-line and market share growth are perpetuated by the quality of customer engagements. 

    Moving from brand message to customer needs requires sales, marketing and technology teams to revise their strategies. To implement this new communication approach, life sciences companies will face some key challenges. Understanding these core challenges is the first step toward customer communication transformation, a journey that leads to growth, cost reductions and enhanced technology value. 

  2. Accelerating Lipid-Based Drug Formulation

    Formulation scientistsmust develop and validat robust systems that address the challenges posed by increasingly complex drug candidates, in ever shortening time frames.

  3. Expect The Unexpected: Daiichi Sankyo’s Glenn Gormley Shares Post Interview Insights

    I first met Glenn Gormley, M.D., Ph.D., at the 2014 PhRMA’s (Pharmaceutical Research and Manufacturers of America) annual meeting in Washington, D.C. At the time, I was engaged in a conversation with James (Mit) Spears, EVP and general counsel for PhRMA, and so my discussion with Dr. Gormley was brief. However, our encounter reminded me of an idea I once had for doing an article about Daiichi Sankyo. Though the company has a lengthy history, it had little experience in the area of oncology R&D. As Gormley is the senior executive officer and global head of R&D at Daiichi Sankyo Co., Ltd., as well as chairman of the board, executive chairman and president of Daiichi Sankyo, Inc, I thought perhaps he could share some insight on the company’s approach to entering into the field of developing cancer therapeutics. We conducted our formal interview on June 30, 2014. It resulted in the September 2014 Life Science Leader magazine cover feature — How Daiichi Sankyo Is Venturing Into The Unfamiliar Terrain Of Oncology R&D.

    As is my custom, I provide interviewees with questions in advance to guide our discussion. After an article is published, it is rare for me to revisit these questions. Further, it is unheard of for me to receive legally approved written responses to my interview questions — especially after an article is complete. But with Glenn Gormley, I have come to expect the unexpected. What follows are the previously unpublished written responses to my interview questions, which serve to shed additional insight into Daiichi Sankyo’s approach to entering the field of oncology drug development.  

  4. Automated pH Adjustment In An Intelligent Single-Use Mixing Platform

    Most pH adjustment process steps in single-use biomanufacturing require manual manipulation of the product and vessel, including off-line sampling, pH measurement, and the addition of acid and base.

  5. Are Today’s Processes Efficient Enough For The Future Of Vaccine And Viral Vector Production?

    By recognizing the limitations of today’s production processes, the industry may be able to overcome the challenges, complexity, and high cost of manufacturing vaccines and viral vector-based therapies.

  6. How To Rapidly Create Single-Use Biomanufacturing Capacity

    To meet therapy production demands, the industry needs to have the right capacity, in the right locations. Increasingly, single-use technologies are being seen as flexible and cost-effective solutions.

  7. Process For Scale-Up Of Adherent Vero Cells From Static Cell Factories To Influenza Production

    In cell culture-based vaccine production, scale-up of adherent cells is challenging. This study shows a process for scaling up adherent Vero cells from static cell factories to influenza production at 50 L scale using WAVE Bioreactor™ systems and ReadyToProcess single-use equipment.

  8. The Cold Chain: Asking The Right Questions

    The concept of cold chain shipping is decades old, but it wasn’t until the last several years that industry has seen great advances in technology, processes and standards for moving temperature-sensitive products. By Joe Reedy

  9. CRO increases ROI For Internal Operations And Provides Sponsors Self-Service Clinical Data Analytics

    Atlantic Research Group is one of the fastest growing and most successful CROs dedicated to being strategic partners for agile and emerging biopharmaceutical companies. ARG has implemented Comprehend to provide Sponsors clinical data insights and access to powerful capabilities, including integrating data across many sources. Comprehend makes clinical data analytics highly intuitive and reporting easy to create and share.

  10. It’s A Regional Sale For Contract Research/Manufacturing

    During the last few weeks I had the opportunity to speak with three experienced and successful business development professionals in the pharmaceutical contract manufacturing arena. They asked to remain anonymous, so I will simply refer to them as Hu, Himani, and Henry. What I got from these discussions with three individuals from three different countries was contrasting views on outsourcing and the future direction of the contract research and manufacturing industry. You can look at these as different world views, or to put it more accurately, different regional views.